Meeting Format and Agenda

To begin each module, results of interactive audience polling using networked iPads will be juxtaposed with the findings from a comprehensive survey comprising case-based and related management questions completed by 25 tumor-specific clinical investigators prior to the meeting. Each faculty member will then deliver a presentation reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the surveys. After each presentation, moderated panel discussion will take place to generate other relevant perspectives and dialogue.

MODULE 1: Induction and Maintenance Therapy for Multiple Myeloma (MM) — Dr Fonseca

• Longer-term follow-up and emerging data with novel front-line triplets (eg, RVD lite, KRd)
• Results from the Phase III ALCYONE study and FDA approval of daratumumab with bortezomib, melphalan and prednisone for newly diagnosed, transplant ineligible patients
• Other ongoing trials evaluating novel agents (eg, elotuzumab, ixazomib, panobinostat) as a component of induction therapy
• Clinical trial evidence supporting maintenance and consolidation therapy for patients with normal- and high-risk disease
• Available platforms, clinical significance and current nonresearch applications for minimal residual disease (MRD) assessment in MM

MODULE 2: Management of Relapsed/Refractory (R/R) MM; Novel Strategies Under Active Investigation — Dr Richardson

• Impact of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology on therapeutic decision-making
• Optimal selection, sequencing and combining of available agents for patients with R/R disease
• Early efficacy and safety results with BCMA (B-cell maturation antigen)-targeted chimeric antigen receptor (CAR) T-cell therapy in MM
• Ongoing investigation of venetoclax and potential clinical role, particularly in patients with t(11;14)

MODULE 3: Chronic Lymphocytic Leukemia (CLL) — Dr Davids

• Utility of existing and emerging biomarkers (eg, del[17p], IGHV mutations, TP53 mutations, complex karyotype, MRD) and implications for clinical decision-making
• Key efficacy and safety findings from the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab for R/R CLL; potential role of venetoclax for patients without del(17p)
• Mechanism of action, early safety and activity and ongoing Phase III investigation of acalabrutinib in CLL
• Emerging research information and ongoing evaluation of novel combination approaches (eg, venetoclax/ibrutinib, ibrutinib/FCR) for untreated or R/R CLL

MODULE 4: Hodgkin Lymphoma (HL) — Dr Younes

• Results from the Phase III ECHELON-1 trial evaluating brentuximab vedotin (BV) with AVD versus ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as front-line therapy for advanced classical HL; clinical implications of the recent FDA approval of BV and AVD as first-line therapy
• Indications for and practical considerations with the use of BV as consolidation therapy after autologous stem cell transplant
• Response rates, durability of responses and long-term outcomes in patients receiving anti-PD-1/PD-L1 antibodies for R/R HL
• Available data with and ongoing investigation of anti-PD-1/PD-L1 antibody therapy in combination with other targeted and immunotherapeutic agents (eg, BV, anti-CTLA-4 antibodies)

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Ansell

• Similarities and differences among available and developmental CAR T-cell platforms with established efficacy in DLBCL
• FDA approvals and current clinical roles of axicabtagene ciloleucel and tisagenlecleucel for DLBCL and other aggressive lymphomas
• Patient selection and practical considerations for the administration of CAR T-cell therapy
• Available research information with and ongoing investigation of lenalidomide and ibrutinib for newly diagnosed and R/R DLBCL

MODULE 6: Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) — Dr Sehn

• FDA approval and integration of obinutuzumab-based induction and maintenance therapy for previously untreated FL
• Clinical and research implications of the Phase III RELEVANCE trial results in newly diagnosed patients; current clinical role of the “R-squared” regimen of lenalidomide/rituximab for R/R disease
• Mechanism of action of, available data with and FDA approval of copanlisib for R/R FL
• Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in MCL
• Clinical research data supporting the recent FDA approval of acalabrutinib in MCL; patient selection for this approach in routine practice